In Phase 2 Trial, Orencia Prevented Graft-Versus-Host Disease After Stem Cell Transplant – Immuno-Oncology News
Immuno-Oncology News |
In Phase 2 Trial, Orencia Prevented Graft-Versus-Host Disease After Stem Cell Transplant
Immuno-Oncology News “Given the serious threat of graft-versus-host disease, new approaches to make stem cell transplants safer for patients remain a critical unmet need,” Kean said in a press release. “To see such striking results in patients at extremely high risk for … Immunotherapy drug nearly eliminates severe acute graft-versus-host disease |
